Study on Glofitamab with Rituximab and Chemotherapy for High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• Patients who have not been treated before and have CD20-positive diffuse large B-cell lymphoma (DLBCL).
• Includes specific types of DLBCL, such as those with certain genetic markers (MYC, BCL2, BCL6).
• Patients with transformed follicular lymphoma may be eligible after consultation.
• Must have a performance status score of 0 to 2, indicating good overall health.
• Must have a life expectancy of at least 6 months.
• Must provide blood samples for biomarker testing before starting treatment.
• Must have at least one measurable lymphoma lesion on a PET/CT scan.
• Heart function must be adequate, with a left ventricular ejection fraction of 50% or higher.
• Must have good blood cell production and function.
• Must agree to use contraception during the study.
• Additional requirement for high-risk participants: Must have a plasma sample showing high-risk ctDNA levels.

Exclusion Criteria

• Patients with certain types of lymphoma, such as gray-zone lymphoma, primary mediastinal large B-cell lymphoma, and others.
• Patients who cannot tolerate any components of the R-CHOP regimen due to allergies or previous reactions.
• Patients who have received prior treatment for indolent lymphoma.
• Patients who have had a solid organ or stem cell transplant.
• Patients who have previously been treated for DLBCL or high-grade B-cell lymphoma, except for short-term steroid treatment.
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study or within a specified time after treatment.